By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating in Boston, Massachusetts, by NewsRx journalists, research stated, "MicroRNAs (miRNAs) have been broadly implicated in cancer, but their exact function and mechanism in carcinogenesis remain poorly understood. Elevated miR-17 similar to 92 expression is frequently found in human cancers, mainly due to gene amplification and Myc-mediated transcriptional upregulation."
The news reporters obtained a quote from the research from Harvard University, "Here we show that B cell-specific miR-17 similar to 92 transgenic mice developed lymphomas with high penetrance and that, conversely, Myc-driven lymphomagenesis stringently requires two intact alleles of miR-17 similar to 92. We experimentally identified miR-17 similar to 92 target genes by PAR-CLIP and validated select target genes in miR-17 similar to 92 transgenic mice. These analyses demonstrate that miR17 similar to 92 drives lymphomagenesis by suppressing the expression of multiple negative regulators of the PI3K and NF kappa B pathways and by inhibiting the mitochondrial apoptosis pathway. Accordingly, miR-17 similar to 92-driven lymphoma cells exhibited constitutive activation of the PI3K and NF kappa B pathways and chemical inhibition of either pathway reduced tumour size and prolonged the survival of lymphoma-bearing mice."
According to the news reporters, the research concluded: "These findings establish miR-17 similar to 92 as a powerful cancer driver that coordinates the activation of multiple oncogenic pathways, and demonstrate for the first time that chemical inhibition of miRNA downstream pathways has therapeutic value in treating cancers caused by miRNA dysregulation."
For more information on this research see: MicroRNA-17 similar to 92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. Embo Journal, 2013;32(17):2377-2391. Embo Journal can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA (see also technology.html">Biotechnology).
Our news correspondents report that additional information may be obtained by contacting H.Y. Jin, Harvard University, Sch Med, Columbus Children's Hospital, Immune Dis InstProgram Cellular & Mol Med, Boston, MA, United States. Additional authors for this research include H. Oda, M.Y. Lai, R.L. Skalsky, K. Bethel, J. Shepherd, S.G. Kang, W.H. Liu, M. Sabouri-Ghomi, B.R. Cullen, K. Rajewsky and C.C. Xiao.
Keywords for this news article include: Biotechnology, Boston, Therapeutics, Massachusetts, United States, Lymphoma Gene Therapy, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC